Clene Demonstrates Strengthened ALS Survival Benefit with CNM-Au8® Treatment

Stock Information for Orchestra BioMed Holdings Inc Com

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Orchestra BioMed Holdings Inc Com

Clene Presents Evidence of Remyelination and Neuronal Repair With CNM-Au8® Treatment At the American Academy of Neurology Late-Breaking Science Session
Clene to Present at the Jones Healthcare and Technology Innovation Conference
Clene Reports Full Year 2024 Financial Results and Recent Operating Highlights
Clene to Present at the 37TH Annual Roth Conference
Clene Inc. Rob Etherington, CEO, and Morgan Brown, CFO, to Present at the Investor Summit Virtual on March 11
Clene and APST Enter Into an Agreement to Support FDA's Recommendation for Long-Term NfL Biomarker Analyses of CNM-Au8®'s Impact on NfL Reduction
Clene Improves Cash Position and Runway by Securing New Debt Facility to Pay Off Existing Senior Loan
FDA Provides Roadmap for Accelerated Approval Pathway Through Submission of Additional CNM-Au8® Biomarker Data in ALS

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.